BARBARA KLENCKE, M.D.
Dr. Barbara J. Klencke is a seasoned drug development executive with expertise in oncology and more than 20 years of experience across both pharmaceutical and biotech companies. From 2015 until 2023, she served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc., acquired by GlaxoSmithKline in 2022. Dr. Klencke has served, currently or previously, as an independent board member of TScan Therapeutics, Inc., Xencor, Immune-Onc Therapeutics, Inc., and Lexent Bio, Inc. From 2011 to 2015, Dr. Klencke served as Senior Vice President, Global Development at Onyx Pharmaceuticals Inc., which was acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs during her tenure at Genentech, Inc. from 2003 to 2011. Throughout her career, she has played a major role in the successful development, approval and early commercialization of a number of important oncology products. Dr. Klencke completed her Internal Medicine and Hematology and Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology, focusing on clinical research, from 1995 to 2002. She holds a Bachelor of Science from Indiana University and a Doctor of Medicine from the University of California, Davis.